<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02626780</url>
  </required_header>
  <id_info>
    <org_study_id>GIDAA-01</org_study_id>
    <nct_id>NCT02626780</nct_id>
  </id_info>
  <brief_title>Adipose-derived SVF for Treatment of Alopecia</brief_title>
  <official_title>Adipose-derived Stromal Vascular Fraction (SVF) Injections to Stimulate Hair Regrowth for Androgenetic Alopecia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The GID Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The GID Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general objective of this study is to conduct a safety and feasibility study of a single
      injection of autologous adipose-derived SVF for the treatment of alopecia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (safety)</measure>
    <time_frame>6 months</time_frame>
    <description>Adverse events will be recorded and evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Growth of new hair</measure>
    <time_frame>6 months</time_frame>
    <description>Hair density (number of hairs per square centimeter) will be measured before treatment and compared to the same measurements after ttreatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hair thickness</measure>
    <time_frame>6 months</time_frame>
    <description>Hair thickness (mm) will be measured before treatment and compared to the same measurements after treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <arm_group>
    <arm_group_label>SVF Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous adipose-derived SVF will be injected into a small (approximately 2x2cm) area of the scalp in men or women with androgenic alopecia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GID SVF-2</intervention_name>
    <description>Comparison of the number and thickness of hair before and after treatment of autologous adipose-derived SVF.</description>
    <arm_group_label>SVF Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females 18 - 60 years of age and older that have been diagnosed with
             androgenetic alopecia.

          2. Subjects will be in good health (ASA Class I-II) with a BMI &lt; 35. Must have at least a
             2cm x 2cm spot on the scalp which shows evidence of alopecia without scarring or
             traumatic injury

          3. Able and willing to make the required study visits.

          4. Able and willing to give consent and follow study instructions.

          5. Must speak, read and understand English

        Exclusion Criteria:

          1. History of bleeding disorders, anticoagulation therapy that cannot be stopped 14 days
             prior to injection

          2. Allergic to lidocaine, epinephrine, valium or sodium phosphate

          3. Individuals with a propensity for keloids

          4. Individuals with diminished decision-making capacity will not be included in this
             research study

          5. Current use of anti-inflammatory or anticoagulation medications that affect bleeding
             or are for bleeding disorders. These include: Plavix, Warfarin (Coumadin, Jantoven,
             Marfarin). In addition, if any of the following medicines are used two (2) weeks prior
             to surgery the patient will be ineligible.

          6. Use of concomitant treatments, including topical medications, oral medications,
             meso-therapy, non-ablative fractional laser treatment, low-level laser therapy,
             interfollicular PRP injection and hair transplantation within the preceding 6 months.

          7. All smokers and other tobacco users.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Maxwell Aesthetics</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renew Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2015</study_first_submitted>
  <study_first_submitted_qc>December 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2015</study_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>April 24, 2018</submitted>
    <returned>May 23, 2018</returned>
    <submitted>May 23, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

